Halozyme Therapeutics (NASDAQ:HALO) Director Sells $140,500.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Bernadette Connaughton sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $70.25, for a total transaction of $140,500.00. Following the completion of the transaction, the director directly owned 40,123 shares of the company’s stock, valued at $2,818,640.75. This represents a 4.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Bernadette Connaughton also recently made the following trade(s):

• On Monday, December 1st, Bernadette Connaughton sold 829 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $71.60, for a total value of $59,356.40.
• On Monday, November 10th, Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $68.48, for a total value of $136,960.00.

Halozyme Therapeutics Trading Down 4.0%

HALO opened at $72.13 on Friday. Halozyme Therapeutics, Inc. has a 12 month low of $47.50 and a 12 month high of $79.50. The stock has a market capitalization of $8.48 billion, a price-to-earnings ratio of 15.19, a PEG ratio of 0.33 and a beta of 0.94. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.59 and a quick ratio of 1.37. The business has a fifty day moving average price of $68.13 and a 200 day moving average price of $66.46.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.63 by $0.09. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The company had revenue of $354.26 million for the quarter, compared to analyst estimates of $339.18 million. During the same quarter last year, the company earned $1.27 EPS. Halozyme Therapeutics’s revenue for the quarter was up 22.1% compared to the same quarter last year. Sell-side analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Halozyme Therapeutics

Several large investors have recently bought and sold shares of the stock. DLD Asset Management LP increased its position in shares of Halozyme Therapeutics by 20.0% during the third quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock worth $2,200,200,000 after purchasing an additional 5,000,000 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its position in shares of Halozyme Therapeutics by 29.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock valued at $241,337,000 after purchasing an additional 749,484 shares during the period. Dimensional Fund Advisors LP grew its stake in Halozyme Therapeutics by 3.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,078,426 shares of the biopharmaceutical company’s stock worth $152,431,000 after buying an additional 63,699 shares during the last quarter. Federated Hermes Inc. increased its position in Halozyme Therapeutics by 294.1% during the third quarter. Federated Hermes Inc. now owns 1,450,704 shares of the biopharmaceutical company’s stock worth $106,395,000 after buying an additional 1,082,638 shares during the period. Finally, LSV Asset Management increased its position in Halozyme Therapeutics by 0.9% during the third quarter. LSV Asset Management now owns 1,266,027 shares of the biopharmaceutical company’s stock worth $92,850,000 after buying an additional 10,787 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analysts Set New Price Targets

HALO has been the topic of a number of analyst reports. Citizens Jmp raised their price objective on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a report on Tuesday, November 4th. Benchmark increased their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. HC Wainwright restated a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a research note on Friday, December 19th. Wall Street Zen cut Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 6th. Finally, JPMorgan Chase & Co. increased their price objective on Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a report on Monday, October 27th. Eight analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $76.45.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.